# Amgen drops ph. 1 obesity drug, upping pressure on MariTide

> **Open Intelligence Dossier** · First detected: 2026-08-05 03:07 UTC · Category: Business

## Executive Summary
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Amgen drops ph. 1 obesity drug, upping pressure on MariTide" is generating significant coverage in the Business category, with 10 articles from 10 distinct sources tracked by PULSE so far.


Outlets currently covering the story include qz.com, PR Newswire, Breakingthenews.net and FirstWord PHARMA. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| qz.com | Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513 | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxPY1VtQWRMdWN0LXluYTIxTDlKVWRrZnFseGFBV2l6UzA5dFdXM1hQTXNCdHUwX29sUzFyZU5qLVhETDJ4U1ktQWpiUVFCT3Z0QjJ0OXo3SWswQWpoWlRRNDV4bnVLcjNfcEtUOUo4MWh0Tko5Z0tkQjlZYTl1NGFZZDJkOA?oc=5) |
| PR Newswire | AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQX1ZISlctV0dzM1p1MzlNUmVjTG5xeDdKMGZQcDNYX3k5WFRTVnZZdXp3OUw0RkEwa3JwQWxoVXdWQmJEUFp1Zk5NRXdWWXQyUUVScDAydFZWM3ZoQ2pSQ2x6WTRoMnNZUnNlaWpBbGRfcGtPMHY1Ny1NNWtKQ0pqUUkzaGpYU2RpNDlhYjlobFZQYVd3MjNHV3pqcDA3VE1GSi1ncGpVWEUxZUU?oc=5) |
| Breakingthenews.net | Amgen Q2 revenue tops projections at $10.1B, up 10% | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxPb3BsVW5oeVUxVm1ZRnVuaURFRWV1cW0yS2FObi1SVzJPem9EQzlwV3hPblJxeE4yUXgxUUxwUkRLemxZcXJrc0J4MmpRYjdPLXA3QlEwNDJJdTRMUnlyVm1ubmFBbE1UbEdQVV9iZkhfZWJBcHRfelpkMUk0dTk0UGNGZVoxa19QUGdXWGVqQll2SFRLZnNPc09ka3B4NTBt?oc=5) |
| FirstWord PHARMA | Amgen remains bullish on Repatha, axes obesity asset in 2Q report | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5lZE1KeE0xZEd4aVEyU3ZlN0VZcm9QcmZ4Qm5FZ0lpUDJGSzM2TERFeGthRmhRY2ROYVF6WG9xU01VMlNGX3VDTHNaSHdMNHc0NGg4?oc=5) |
| Yahoo Finance | Amgen (AMGN) To Report Earnings Tomorrow: Here Is What To Expect | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxNcVVhSTdJM0dYVmEwTGtMQ25ZdV9PZC1HZkRVaHItanJUeFozMF9mNGxicFl6S0RzNFJjQzlYcXBnM18yOC1wRVkzaFFlODBJMFhfV3FQQjBheTNkYjFOT0llY2dfeEMybHN2NG5PekRhVmFfd2hUX1RGMUVzdm0ya1hBNVlrMHpJRzRQQVJkaXNxenQ4blN6R0xVampaV1V0WEE?oc=5) |
| bloomberg.com | Amgen Lifts Outlook After Blockbuster Sales Top Expectations | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOS2Q3VTJhRmJJOVJhemh1RlFwcWdqWGVwRFZfQ1VJVjllOUx0QjJESVJyMEROeUZxU0huakRYVkQ0R2FLbTlvaXZFQnBiUWY2NGtFbTZTM0hqWTBoaXhmTm1SNGVVSFJPQkJLam9wYXprdmZqamxqdFNUYm0yTnBUWWZGY2pLT05lemh1TkNNd0lZQmhldTFtbHA2VW1IbUdfQnBvTzAzT2pSbDhKRFVpWg?oc=5) |
| Investor's Business Daily | Amgen Boosts Sales View By $1 Billion After Smashing Views | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxQSFVxUWRiaTRpakEwWklpdWdubmtRUjUtTVhCT0d2aUxYRHZ1Nml0ZEFUYUJKVlNjV0xWUDA5Xy1CMGduUHY4ZEVzeFNVLU5SaWVXS1FOOWZTODBhUWNRLV8wTndjNE55QnVRb2kxbEZxeXVuMXI4UkxkSG8yTUd0VWtRMA?oc=5) |
| Fierce Pharma | Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxPaW9BNDJKd3c2cGcxX3d1bnE3azZBSF8zN045ZHdYaFd3Tkx0WlhSMG1QTnJheDdzRDVRanJ6SW84U3RYY2NrdHhwSTlrY2ZNLXdxZ2sxM3VKYXkzWTFfRUJNdmVEVjRPSExoa01GelAteWVLeGVZTnAxWjdkREtrZGFrMjJ1QzkwLVprY3lrZzdyU1M3UEM0SVBMUlFzdjNBXzdHUE0yNGZ1dGZFaXpod2JsTDRTd3NTMVE?oc=5) |
| WSJ | Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment | [Source Link](https://news.google.com/rss/articles/CBMizgFBVV95cUxQNzFRRU5LeWlyZy1WcGEtVC1UYjRWSFZTeG03NDdrNFE1NTVRWlVlSGFld0E4NFhFUHJBMnp1aDlKLWM5NUdVRndvcDlaenhCVDFGYW03LXJZQUp2NkFLbDk5SlhuRjZ0eTNtMnJ5ODBSbWU2d2pYdUpvQ3NOSDlGQmxqVTZZajc4bjFSazByMGtfQWtKVmtnT1kxdVFYZENFcG1udU00d1lkUXlnMkc4cHBtb0VjNzZzaFdGUmU0YkxDY2dYeVdIdGZ0M05TZw?oc=5) |
| Fierce Biotech | Amgen drops ph. 1 obesity drug, upping pressure on MariTide | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxPTllQeUpSUVFQdm1fd3ZsbGZZR0x3REJ0cUNZeDdzUGhEUndsX1ZUUXpSZmpEeVR4c0o1TXVaQzJhSGh0alhLNkU2N0QxQ0dGbENwRXZVb1ljN3ZEMEtqSDRYbER0NGVEXzVfa0ZscEFHNm9zMTVBZ1Vza2c4dU12aUY5dF9qTGdpYTBGazlJMzRxSnFXd2VySjNlS2VZckxI?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-08-05/amgen-drops-ph-1-obesity-drug-upping-pressure-on-maritide*